Corrigendum to "Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib"

Affiliations

¹ Laboratory of Pathophysiology of Cachexia and Metabolism of Skeletal Muscle, IRCCS San Raffaele Pisana, 00166 Rome, Italy.
² Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
³ Bionem Laboratory, Department of Experimental and Clinical Medicine, Magna Graecia University, 88100 Catanzaro, Italy.
⁴ Cardiovascular and Cell Sciences Institute, St George's, University of London, Cranmer Terrace, London, UK.

Published Erratum

Stefania Gorini et al. Oxid Med Cell Longev. 2019.

. 2019 Jun 26:2019:9601435.

doi: 10.1155/2019/9601435. eCollection 2019.

¹ Laboratory of Pathophysiology of Cachexia and Metabolism of Skeletal Muscle, IRCCS San Raffaele Pisana, 00166 Rome, Italy.
² Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
³ Bionem Laboratory, Department of Experimental and Clinical Medicine, Magna Graecia University, 88100 Catanzaro, Italy.
⁴ Cardiovascular and Cell Sciences Institute, St George's, University of London, Cranmer Terrace, London, UK.

Abstract

[This corrects the article DOI: 10.1155/2018/7582730.].

Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib.
Gorini S, De Angelis A, Berrino L, Malara N, Rosano G, Ferraro E. Gorini S, et al. Oxid Med Cell Longev. 2018 Mar 18;2018:7582730. doi: 10.1155/2018/7582730. eCollection 2018. Oxid Med Cell Longev. 2018. PMID: 29743983 Free PMC article. Review.

1. Gorini S., De Angelis A., Berrino L., Malara N., Rosano G., Ferraro E. Chemotherapeutic drugs and mitochondrial dysfunction: focus on doxorubicin, trastuzumab, and sunitinib. Oxidative Medicine and Cellular Longevity. 2018;2018:15. doi: 10.1155/2018/7582730.7582730 - DOI - PMC - PubMed